The once-a-day era is upon us

AIDS Reader

Volumn 12, Issue 2, 2002, Pages 56-58

  Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Adherence; Antiretroviral therapy; Dosing regimens

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR;

ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FOLLOW UP; FOOD DRUG INTERACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; PATIENT COMPLIANCE; SELF REPORT; TABLET; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS;

EID: 0036194062     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Abacavir/Combivir (abc/com) is comparable to indinavir/Combivir (idv/com) in HIV-1 infected antiretroviral therapy naive adults: Preliminary results of a 48-week open-label study (CNA3014)
2. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in FHV-1-infected patients with undetectable plasma HIV-1 RNA
3. Switch to Trizivir versus continued HAART provides equivalent HIV-1 RNA suppression at 48 weeks (TRIZAL-AZL30002)
4. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads - A prospective, randomized, multicenter, open-label study (DMP 049)
5. Once-a-day treatment for HIV infection: Final 48-week results
6. Once-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment-naive HIV-infected adults: 64-week follow-up of the ANRS 091 trial
7. A systematic review of the associations between dose regimens and medication compliance
8. Short cycle intermittent HAART: A pilot study
9. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture
10. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial